These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
425 related items for PubMed ID: 26529285
21. Intrahepatic osteopontin signaling by CREBZF defines a checkpoint for steatosis-to-NASH progression. Ma F, Liu Y, Hu Z, Xue Y, Liu Z, Cai G, Su W, Zheng Z, Fang X, Yan X, Ding D, Sun X, Jiang Y, Wei S, Li W, Zhao J, Zhang H, Li H, Xiao D, Zhang C, Ying H, Qin J, Gao X, Dai X, Fu W, Xu Y, Li Y, Cui A. Hepatology; 2023 Nov 01; 78(5):1492-1505. PubMed ID: 36680394 [Abstract] [Full Text] [Related]
32. Micro-RNA 21 inhibition of SMAD7 enhances fibrogenesis via leptin-mediated NADPH oxidase in experimental and human nonalcoholic steatohepatitis. Dattaroy D, Pourhoseini S, Das S, Alhasson F, Seth RK, Nagarkatti M, Michelotti GA, Diehl AM, Chatterjee S. Am J Physiol Gastrointest Liver Physiol; 2015 Feb 15; 308(4):G298-312. PubMed ID: 25501551 [Abstract] [Full Text] [Related]
33. p16 deficiency promotes nonalcoholic steatohepatitis via regulation of hepatic oxidative stress. Lv F, Wu J, Miao D, An W, Wang Y. Biochem Biophys Res Commun; 2017 Apr 29; 486(2):264-269. PubMed ID: 28286271 [Abstract] [Full Text] [Related]
34. Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis. Zhu C, Kim K, Wang X, Bartolome A, Salomao M, Dongiovanni P, Meroni M, Graham MJ, Yates KP, Diehl AM, Schwabe RF, Tabas I, Valenti L, Lavine JE, Pajvani UB. Sci Transl Med; 2018 Nov 21; 10(468):. PubMed ID: 30463916 [Abstract] [Full Text] [Related]
35. Cyclooxygenase-2 expression in hepatocytes attenuates non-alcoholic steatohepatitis and liver fibrosis in mice. Motiño O, Agra N, Brea Contreras R, Domínguez-Moreno M, García-Monzón C, Vargas-Castrillón J, Carnovale CE, Boscá L, Casado M, Mayoral R, Valdecantos MP, Valverde ÁM, Francés DE, Martín-Sanz P. Biochim Biophys Acta; 2016 Sep 21; 1862(9):1710-23. PubMed ID: 27321932 [Abstract] [Full Text] [Related]
36. Pharmaceutical Efficacy of Gypenoside LXXV on Non-Alcoholic Steatohepatitis (NASH). Lee JH, Oh JY, Kim SH, Oh IJ, Lee YH, Lee KW, Lee WH, Kim JH. Biomolecules; 2020 Oct 08; 10(10):. PubMed ID: 33050067 [Abstract] [Full Text] [Related]
37. Thrombin cleavage of osteopontin controls activation of hepatic stellate cells and is essential for liver fibrogenesis. Cui G, Chen J, Wu Z, Huang H, Wang L, Liang Y, Zeng P, Yang J, Uede T, Diao H. J Cell Physiol; 2019 Jun 08; 234(6):8988-8997. PubMed ID: 30350863 [Abstract] [Full Text] [Related]
38. Significance of MR/OPN/HMGB1 axis in NAFLD-associated hepatic fibrogenesis. Tang M, Jia H, Chen S, Yang B, Patpur BK, Song W, Chang Y, Li J, Yang C. Life Sci; 2021 Jan 01; 264():118619. PubMed ID: 33091447 [Abstract] [Full Text] [Related]
39. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice. Xu B, Jiang M, Chu Y, Wang W, Chen D, Li X, Zhang Z, Zhang D, Fan D, Nie Y, Shao F, Wu K, Liang J. J Hepatol; 2018 Apr 01; 68(4):773-782. PubMed ID: 29273476 [Abstract] [Full Text] [Related]
40. Inhibiting Interleukin 11 Signaling Reduces Hepatocyte Death and Liver Fibrosis, Inflammation, and Steatosis in Mouse Models of Nonalcoholic Steatohepatitis. Widjaja AA, Singh BK, Adami E, Viswanathan S, Dong J, D'Agostino GA, Ng B, Lim WW, Tan J, Paleja BS, Tripathi M, Lim SY, Shekeran SG, Chothani SP, Rabes A, Sombetzki M, Bruinstroop E, Min LP, Sinha RA, Albani S, Yen PM, Schafer S, Cook SA. Gastroenterology; 2019 Sep 01; 157(3):777-792.e14. PubMed ID: 31078624 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]